Last reviewed · How we verify
NI-1801 in combination with paclitaxel — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
NI-1801 in combination with paclitaxel (NI-1801 in combination with paclitaxel) — Light Chain Bioscience - Novimmune SA.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NI-1801 in combination with paclitaxel TARGET | NI-1801 in combination with paclitaxel | Light Chain Bioscience - Novimmune SA | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NI-1801 in combination with paclitaxel CI watch — RSS
- NI-1801 in combination with paclitaxel CI watch — Atom
- NI-1801 in combination with paclitaxel CI watch — JSON
- NI-1801 in combination with paclitaxel alone — RSS
Cite this brief
Drug Landscape (2026). NI-1801 in combination with paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/ni-1801-in-combination-with-paclitaxel. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab